AWA
ABUS icon

Arete Wealth Advisors’s Arbutus Biopharma ABUS Stock Holding History

Arete Wealth Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,000
Closed -$46K – 708
2024
Q2 		$46K Buy
+15,000
New +$45K ﹤0.01% 707
2024
Q1 		– Sell
-15,000
Closed -$37.5K – 379
2023
Q4 		$37.5K Hold
15,000
– – ﹤0.01% 722
2023
Q3 		$30.4K Hold
15,000
– – 0.01% 488
2023
Q2 		$35K Hold
15,000
– – ﹤0.01% 650
2023
Q1 		$45K Buy
+15,000
New +$42.3K ﹤0.01% 622
2022
Q4 		– Sell
-15,000
Closed -$29K – 634
2022
Q3 		$29K Buy
+15,000
New +$35.3K ﹤0.01% 564
2022
Q2 		– Sell
-15,000
Closed -$45K – 453
2022
Q1 		$45K Hold
15,000
– – ﹤0.01% 500
2021
Q4 		$58K Buy
+15,000
New +$58.3K ﹤0.01% 494

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Arete Wealth Advisors's ABUS Position: Q3 2024 in Review

Arete Wealth Advisors sold out of Arbutus Biopharma (ABUS) in Q3 2024, closing a stake of 15,000 shares — an estimated $46K sold.

Arete Wealth Advisors first reported a position in ABUS in Q4 2021 and held it in 8 quarters. The position peaked at $58K in Q4 2021. 144 funds tracked by Wall St. Rank hold ABUS as of Q3 2024.

  • Arete Wealth Advisors reported no remaining Arbutus Biopharma position as of Q3 2024 after selling out during the quarter.
  • Arete Wealth Advisors sold 15,000 Arbutus Biopharma shares in Q3 2024, an estimated $46K.
  • Arete Wealth Advisors first reported a position in Arbutus Biopharma in Q4 2021 and held it in 8 quarters.
  • Arete Wealth Advisors's Arbutus Biopharma position peaked at $58K in Q4 2021.
  • 144 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2024.

Based on Arete Wealth Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.